Title

Improving Detection of Clinically Significant Prostate Cancer: MRI/TRUS Fusion-Guided Prostate Biopsy

Publication Date

2013

Journal Title

J Urol

Abstract

PURPOSE:: Given the limitations of prostate specific antigen and standard biopsies in detecting prostate cancer (CaP), we evaluate the Cancer Detection Rate (CDR) and external validity of Magnetic Resonance Imaging/Transrectal Ultrasound (MR/TRUS) fusion-guided prostate biopsy system being utilized at NIH. MATERIALS AND METHODS:: Phase-III Trial of MR/TRUS fusion-guided prostate biopsy system with participants enrolled between 2012 and 2013. 153 men consented to the study who underwent a 3T multi-parametric MRI with an endorectal coil for a clinical suspicion for CaP and had lesions classified into low or moderate/high risk for CaP. MR/TRUS fusion-guided biopsies and standard 12-core prostate biopsies were performed, and 105 men were eligible for analysis. RESULTS:: The mean age and PSA were 65.8 years and 9.5ng/mL respectively. The overall CDR was 62.9 % (66/105). The CDR in those with moderate/high risk on MP-MRI was 72.3% (47/65) versus 47.5% (19/40) in those classified as low risk for CaP (p

Volume Number

191

Issue Number

6

Pages

1749-54

Document Type

Article

EPub Date

2013/12/18

Status

Faculty; Northwell Researcher

Facility

School of Medicine; Northwell Health

Primary Department

Urology

Additional Departments

Radiology

PMID

24333515

DOI

10.1016/j.juro.2013.12.007